β-dystroglycan Antibody (B-6): sc-165998

β-dystroglycan Antibody (B-6) is a mouse monoclonal IgG1 kappa light chain antibody that detects β-dystroglycan in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). β-dystroglycan (B-6) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. Dystroglycan plays a crucial role as a cell surface receptor for several extracellular matrix components, including laminins, agrin, and perlecan, which are essential for basement membrane formation during early development and proper laminin organization on the cell surface. β-dystroglycan′s location at the cell membrane facilitates interaction between the extracellular matrix and cytoskeleton, influencing cell adhesion, migration, and signaling pathways. β-dystroglycan forms a complex with α-dystroglycan, anchoring α-dystroglycan to the cell membrane, and participates in larger multimolecular complexes including dystrophin at the sarcolemma and utrophin at the neuromuscular junction, highlighting β-dystroglycan′s importance in muscle function and neuromuscular transmission. β-dystroglycan′s ability to cluster nicotinic acetylcholine receptors at the neuromuscular junction further underscores β-dystroglycan′s significance in synaptic transmission and muscle contraction.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

β-dystroglycan Antibody (B-6) References:

1. The WW domain of dystrophin requires EF-hands region to interact with beta-dystroglycan.  |  Rentschler, S., et al. 1999. Biol Chem. 380: 431-42. PMID: 10355629
2. Plasticity of secondary structure in the N-terminal region of beta-dystroglycan.  |  Boffi, A., et al. 2001. Biochim Biophys Acta. 1546: 114-21. PMID: 11257514
3. Localization of phospho-beta-dystroglycan (pY892) to an intracellular vesicular compartment in cultured cells and skeletal muscle fibers in vivo.  |  Sotgia, F., et al. 2003. Biochemistry. 42: 7110-23. PMID: 12795607
4. Concerted mutation of Phe residues belonging to the beta-dystroglycan ectodomain strongly inhibits the interaction with alpha-dystroglycan in vitro.  |  Bozzi, M., et al. 2006. FEBS J. 273: 4929-43. PMID: 17018058
5. beta-Dystroglycan modulates the interplay between actin and microtubules in human-adhered platelets.  |  Cerecedo, D., et al. 2008. Br J Haematol. 141: 517-28. PMID: 18341635
6. Enzymatic processing by MMP-2 and MMP-9 of wild-type and mutated mouse β-dystroglycan.  |  Sbardella, D., et al. 2012. IUBMB Life. 64: 988-94. PMID: 23129308
7. VHL-dependent regulation of a β-dystroglycan glycoform and glycogene expression in renal cancer.  |  Aggelis, V., et al. 2013. Int J Oncol. 43: 1368-76. PMID: 23970118
8. Sustained down-regulation of β-dystroglycan and associated dysfunctions of astrocytic endfeet in epileptic cerebral cortex.  |  Gondo, A., et al. 2014. J Biol Chem. 289: 30279-30288. PMID: 25228692
9. α-Dystroglycan hypoglycosylation affects cell migration by influencing β-dystroglycan membrane clustering and filopodia length: A multiscale confocal microscopy analysis.  |  Palmieri, V., et al. 2017. Biochim Biophys Acta Mol Basis Dis. 1863: 2182-2191. PMID: 28572004
10. Postmortem immunohistochemical alterations following cerebral lesions: A possible pathohistological importance of the β-dystroglycan immunoreactivity.  |  Szöllősi, D., et al. 2018. Neuropathology. 38: 207-217. PMID: 29266551

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-β-dystroglycan Antibody (B-6) has 0 citations in a variety of scientific publications.

Primary antibodies like Anti-β-dystroglycan Antibody (B-6) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

β-dystroglycan Antibody (B-6) Specifications

Alternate Product Name: β-dystroglycan

Product Clone Name: B-6

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 831-895

Epitope Target: dystroglycan precursor

Epitope Species: human

Product Reactivity/Detection: β-dystroglycan

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 0 citations in various scientific publications

Available Conjugates/Forms for β-dystroglycan Antibody (B-6): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin

The preferred β-dystroglycan antibody is β-dystroglycan Antibody (4F7): sc-33702.